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THE ECONOMICS OF VECTOR CONTROL STRATEGIES FOR
CONTROLLING TROPICAL DISEASES
ANNE MILLS
London School of Hygiene and Tropical Medicine and London School of Economics and Political
Science, London, United Kingdom
Abstract. This paper describes the techniques of economic evaluation and how they
can help improve the efficiency of vector control strategies for controlling tropical diseases.
The differences among the techniques are clarified, and the main components of each
analytical approach are presented, as well as some of the major problems in their appli
cation. The historic evolution of the application of economics to vector control in devel
oping countries is summarized, before analyzing some more recent studies that have ex
plored some of the choices concerning vector control. The paper concludes with some
recommendations for improving the quality and, therefore, the usefulness of studies.
THE UTILITY OF ECONOMICS
The prime concern of the discipline of eco
nomics is with the implications of the scarcity
of resources and the need to make choices on
how best to use them. Given scarce resources,
what criteria should public sector decision-mak
ers use to judge whether a particular action is or
is not worthwhile? The answer is straightfor
ward, even if putting it into practice is not. An
action is good or bad by reference to social ob
jectives, and by reference to the action's costs
(anything that detracts from social objectives)
and its benefits (anything that contributes to so
cial objectives).
This begs thequestionof what arethesocial
objectives.The most obviousone isefficiency,
since the greater the efficiency with which re
sources are used, the more it is possible to
achieve with them. In particular, efficiency in
resource use contributes to raising per capita in
come, a universal objective of tropical countries.
Economic efficiency has two aspects: the first is
operationalefficiency,toproducea givenoutput
at minimum cost or maximize output for a given
cost (thecommon sense notionof efficiency,
which could be referred to as economy); the sec
ond is allocative efficiency, to produce the best
or optimal combination of outputs (that which is
socially desired) by means of the least cost com
bination of inputs.
Efficiency is not however the only objective
governments seek to achieve. Equity, the distri
bution of national income between different
groups in society, may also be an objective, as
may others such as employment. In relation to
health, raising health status overall and in rela
tion to particular groups of the population may
themselvesbe objectivesintheirown right.
During the past thirty years, economists have
been increasingly concerned that whereas it is
possible to define the conditions under which a
private market will achieve efficiency, and the
environment that will create the necessary in
centives, such incentives are lacking in public
bureaucracies. In particular, in the absence of
the market, rules are needed to guide resource
allocationdecisions.Thus, since the l950s,
economists have been developing techniques
that can be applied to public sector investment
alternativesto help decidewhich projectswill
have thegreatestnetimpacton socialobjectives
and thus should be implemented. Early efforts
concentrated on developing the technique of
cost-benefitanalysis,in which both costsand
benefits are valued in monetary terms so that
they can be directly compared.' This technique
has been developed into a comprehensive sys
tem for appraisal of investment alternatives in
developing countries,2 and can be used to ana
lyze allocative efficiency.
Cost-benefit analysis is difficult to apply in
the health sector (as discussed later) because of
the problems of placing a value on benefits.
Considerable effort has been put into developing
alternative techniques, particularly that of cost
effectiveness analysis, which takes the objective
of health improvement as given and compares
health effects with costs expressed in monetary
terms. Since the objective is not questioned (and
a value not placed on it), the technique is of
greatestuse inanalyzingoperationalratherthan
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allocative efficiency. In developed countries,
cost-utility analysis has become popular. This
involves weighting effects by a measure of their
utility.
Cost-benefit analysis and cost-effectiveness
analysis are frequently confused; moreover,
there have been recent developments in the tech
nique of cost-effectiveness analysis that bring it
rather closer to cost-benefit analysis. Thus, it is
important to be clear on the distinctions within
the family of techniques. The following are the
components included.3
Costs:
C,â€”Direct costs (the direct resource costs of
implementing an activity)
C2â€”Indirect costs (loss of production associ
ated with being involved in the activity,
e.g., as a patient)
C3â€”Intangible costs (e.g., pain and anxiety
caused by treatment).
Outputs:
Eâ€”Health effects (e.g., reduction in morbid
ity and mortality)
Uâ€”Utility weighted health effects (e.g., as
measured by quality adjusted life years)
Bâ€”Associated economic benefits
B,â€”Direct benefits (savings in treatment or
prevention costs)
B2â€”Indirect benefits (gain in production
because of improved health, or directly
because of project-related income-gener
ating activities)
B3â€”Intangible benefits (the value of health
per se).
Cost analysis includes C, and sometimes C2
as well. Cost-effectiveness analysis in its sim
plest form (the one most frequently found in de
veloping country studies) divides C, (sometimes
plus C2) by E. However, studies in Europe and
the United States now routinely subtract B, and
B2 from C, and C2, producing net costs, before
dividing by E. Cost-utility analysis is calculated
in the same way as cost-effectivenessanalysis,
except that E is replaced by U. Cost-benefit
analysis ideally subtracts all the C components
from all the B components; or divides the Bs by
the Cs. However, no completely satisfactory
means exists for putting a monetary value on B3.
Thus, most studies consider only C, and C2, and
B, and B2. It can clearly be seen that in this
form, cost-benefit analysis adds nothing to the
more complex version of cost-effectiveness
analysis.
The essence of economic analysis is the com
parison of alternative courses of action. In the
ory, therefore, it is undesirable to restrict the
scope of an analysis, once the nature of the
health objective that the alternatives compared
seek to achieve has been specified. For example,
if the objective is to improve health, alternatives
could range across the whole health sector. Ac
cording to this approach, it makes little sense to
consider vector control strategies separately
from other strategies that may control vector
borne diseases, or from other interventions that
may improve health. In practice, however, ana
lytical feasibility and organizational realities
limit to some extent the scope of the choices
evaluated. Vector control activities are frequent
lyorganizedby a singleMinistryof Healthde
partment,which has some discretiontoallocate
resources both among different vector-borne dis
eases and to different vector control strategies.
Moreover, a particular strategy may control sev
eral vector-borne diseases. Therefore, it is useful
for vector control managers to see how econom
icanalysiscan be appliedtotherangeofchoices
open to them. However, it should not be forgot
ten that there will be choices to be faced by
higher level decision-makers concerning the al
location of resources when restricting the bound
aries of the analysis to a particular subset of dis
eases and strategies would risk ignoring
interventions that might improve health at less
cost.
Before discussing the evolution of the appli
cation of economics to vector control strategies
in developing countries, it is important to fore
warn readers of some of the problems in mea
suring these components and doing the analyses.
In relation to costs, cost data are rarely produced
by project accounts: even if project accounts are
available, they may be out of date and inaccu
rate. Shaw provides a useful comment on the
deficiencies of project accounts in relation to de
termining costs for human trypanosomiasis con
trol,4 suggesting that project accounts should
routinelydistinguishcategoriesuch as variable
costs and overhead costs. Another common
problem is that some resources are inputs to
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more than one activity, i.e., costs are joint. This
can provide a particular problem for vector con
trol evaluations where vector control is part of
a water resource development project.5 For ex
ample, Tameim and others were faced with the
problem of deciding what share of water supply
costs should be attributed to schistosomiasis
control in an irrigation scheme in Sudan.6 One
third was allocated to control and the other two
thirds to diarrheal diseases and labor savings,
but without a clear justification. A final concern
about many cost studies is that costs falling on
households and communities are omitted, raising
the possibility that an option may be chosen that
minimizes costs to the government, but has
highersocialcoststhananotheroptionbecause
it imposes costs on households.
In relation to effects, the major problem is that
of predicting (or measuring) them. Ideally, the
endpoint should be in terms of human health,
since thatis what societyvalues.7However,
these data are frequently not available, and in
some circumstances other indicators are ade
quate. Phillips and others define the following
sequence of effects for vector control:5 outputs
of goods and services (e.g., houses sprayed,
ponds cleaned), outcomes on the vector (e.g.,
change in abundance and longevity), outcomes
on human behavior (e.g., use of bed nets), im
pacts on disease (e.g., reduction in morbidity
and mortality),and impactson socioeconomic
variables (e.g., reduction in treatment costs; re
turn from income-generating activities).
For example, output indicators would be ad
equate if the prime concern was with operational
efficiency and if it was extremely likely that a
particular output produced a health status effect.
The choice of indicators of effect is relatively
straightforward when control strategies are being
compared for one disease. If the comparison is
among several diseases, an indicator has to be
chosen that adequately reflects the health status
consequences of all the diseases. In the devel
oping country literature, favored candidates are
discounted healthy years of life8 and disability
adjusted life years.9 These measures represent
the gain in healthy years of life provided by an
intervention and allow for mortality, morbidity,
and disability improvements, and time prefer
ence (preferring benefits sooner rather than lat
er).
In relation to benefits, the major problem is
how to value intangible benefits. The approach
commonly recommended for developed country
studies is to assess people's willingness to pay.'Â°
While theoretically attractive in some respects,
this has the drawback that estimates would re
flect ability to pay (and thus the distribution of
income), and that estimates are extremely diffi
cult to make because on the whole people do
not pay and thus there are few values to observe.
In the absence of better measures, studies in de
veloping countries have used the human capital
approach. This treats health expenditure as an
investment in people that enables them to be
more productive. The main benefits of improved
health are increased production. This approach,
although much used in the past (see below), is
disliked by many economists since it implies
that we value people purely as producers, which
is patently not the case.â€• Nonetheless, increased
production is an important component of bene
fits, but can be included in cost-effectiveness
analysis along with measures of health effect.
Two further points are important when the
components of the analysis are being put togeth
er. First, when costs and effects/benefits are be
ing analyzed over time, a discount rate is applied
to allow for time preference: the fact that people
prefer benefits sooner rather than later. In vector
control studies, the choice of the level of dis
count rate can be important since the higher the
rate, the more heavily are future costs and ben
efits discounted. Cohn demonstrated that the lev
el of discount rate would have affected the
choice between malaria eradication and control
in India,'2 and Little also found that the level of
discount rate would affect the choice of means
to eradicate yellow fever in South America.'3
Second, cost-effectiveness analysis calculates
an average cost and is indifferent to the scale of
effects. However, the average cost may change
with the size of the project. The cost would de
crease if there are economies of scale (the larger
the scale of activity, the lower the unit cost), as
has been demonstrated for source reduction for
salt marsh mosquito abatement in the United
States.'4 It would increase if infected individuals
are harder to locate. Thus, different project sizes
may need to be evaluated. Also, the option with
the lowest cost per unit of health effect may
have fewerhealtheffectsthanan alternative.In
these circumstances, incremental analysis is im
portant, i.e., calculating the additional cost of
achievingadditionaleffectiveness.
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bert, 20 and Bhombore and others;2' none of
these attempted a cost-benefit analysis), and the
relationship is by no means proven, in no small
part because of its complicated nature and the
way in which many households adapt to cope
with ill health (e.g. by reallocating responsibili
ties for productive activities among family mem
bers and reducing leisure time).
The second main criticismof thesestudies
concernstheirrelevanceto policydecisions.In
thecaseof thecost-of-diseasetudies,knowing
the magnitude of the loss is not much help to
policy makers; what matters is whether some
thing can be done about the disease at an af
fordable cost. Moreover, the cost of lost produc
tion is an imperfect reflection of the true burden
of the disease because it ignores any impact on
nonproducers such as the elderly and children.
A similar criticism can be leveled at the cost
benefitanalysessincethese studiesused the
same human capital approach and ignored other,
less tangible benefits of disease control. For ex
ample, Cohn concluded in relation to India that
because malaria control would not only increase
production but also raise population growth,
â€œtheconomic case for malaria control may not
be very strong' â€˜@22This wrongly implies that
there are economic objectives and humanitarian
objectives, and that economic analysis is indif
ferent to the latter. As stated earlier, economics
is concerned with the contribution of projects to
all social objectives, which are likely to include
improving health and not just raising per capita
income.
Despite these shortcomings, policy makers
still call for studies of the economic impact of
particular diseases,23 in the hope that national
development authorities will thereby be persuad
ed of the virtues of investing in health. However,
the technique of greatest value to program man
agers is cost-effectiveness analysis. It avoids the
problem of pretending to value all benefits, and
in addition can address the question of opera
tional efficiency, which should be of concern to
all managers. In recent years, interest in cost and
cost-effectiveness analyses in other parts of the
health sector, e.g., primary health care,24 im
munization programs,25 and diarrheal diseases,26
has grown considerably. With the exception of
the efforts of the Panel of Experts on Environ
mental Management for Vector Control
(PEEM)27 and a few researchers, little attention
seems to have been paid to using economic anal
THE EVOLUTION OF STUDIES ON THE ECONOMICS
OF VECTOR CONTROL STRATEGIES FOR
CONTROLLING TROPICAL DISEASES
The application of economics to vector-borne
diseasehas a long history.The initialconcerns
of analystswere commercial:â€œItisthepurpose
of the Department of Agriculture to place the
prevention of malaria on the farm upon a busi
ness basis. It remains to show what malaria
means to a cotton planter in so many dollars and
cents.â€•5 This focus was not confined to the
United States: a classic study of what malaria
costs India stated that â€œMalaria is an infec
tion that does not kill at the first attack, except
in the most malignant type. It is, however, the
recurrent attacks in the untreated and partially
treated cases that sap the vitality of the masses,
undermine their constitution, reduce their phys
ical stamina and create in them a state of chronic
debility that prevents the full economic value of
the peasantry and industrial workers. Productiv
ity of the soil thus becomes greatly reduced, and
economic distress, poverty, disease and death
follow in its wake.â€•6
This sets the context for the economic anal
yses of vector-borne diseases up to the 1970s.
Studies were of two main types: those that at
tempted to quantify the cost of disease, i.e., its
impact in terms of costs of treatment and pre
vention, and loss of production, and those that
assessed the contribution of vector control to
raisingpercapitaincome througha cost-benefit
analysisthatcompared control(eradication)
costswithsavedexpenditureon preventionand
treatment and production gains. Two different
types of criticism can be leveled at these studies.
The first concerns their lack of empirical foun
dation. The standard approach was to take an
estimate of the total cases of the disease affect
ing productive age groups and multiply this by
the average number of days ill per case and by
some value of a day's work to obtain a total
value for production lost. This approach has
many obvious deficiencies,not the leastof
which istheoftenunrealisticestimatesof days
lost (e.g., 44 days per case of malaria per year
reported by Ortiz'7), and assumptions that days
lost equals production lost, which equals pro
duction gained if control were to be achieved.
Only a few studieshave carefullyinvestigated
the relationship between disease and productiv
ity (e.g., Weisbrod and others,'8 Conly,'9 Audi
AlternativesAnalyticalapproachInvestigatorsNo eCost
analysis
Outcome analysis
Cost-benefit analysisChu
and others@'
Rajagopalan and Panicker35
Schofield andDias@Within
vector controlCost analysisPhillips and Mills37
Gandahusada andothers38Vector
controlversusothercontrol
methods for same diseaseCost
analysis
Cost-effectiveness analysisJordan4Â° Rosenfield and others4'
Shaw4Vector
controlversusotherinter
ventions for different diseasesCost-effectiveness
analysisProst andPrescott42
Jamison and others9
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T1@mit1
Studies illustrating different choices and analytical techniques
ysis to improve the efficiency of vector control
operations in developing countries.
THE CURRENT USE OF ECONOMIC ANALYSIS TO
ANALYZE VECTOR CONTROL STRATEGIES
In the space of this paper, it is not possible to
give a complete description of all the studies that
have used economic analysis to help identify ef
ficient vector control strategies. Instead, to in
dicate the sort of studies that can be done and
the assistance they can provide to decision-mak
ers, five different types of choices concerning
vector control are identified, and illustrative
studiesthathave exploredthesechoicesaredis
cussed. The choices, analytic approaches, and
studies are shown in Table 1. These studies are
not intended to be representative of the whole
literature, but have been chosen to indicate the
usefulness of empirical studies focusing on par
ticular questions of local relevance. Readers
wishing more comprehensive reviews for partic
ular diseases can consult the individual chapters
in Jamison and others9 (particularly those on ma
lana,28 dengue,29 and helminth infection30), Nga
re and Lamounier on onchocerciasis,3' and Bar
low and Grobar32 for a comprehensive review of
economic evaluation studies relating to parasitic
disease control.
The essential features of economic evaluation
are 1) the comparison of the additional costs and
consequences following from implementing an
intervention, and 2) the comparison of the costs
and consequences of alternative interventions.
That said, there are many studies that do not
make either type of comparison, and many oth
ers that do one but not the other.33 Although par
tial analyses,'Â° they can still provide some useful
information. For example, Chu and others cal
culated the annual cost of cercarial transmission
control in the Volta Lake in Ghana, including
the combined cost of molluscicides, weed re
moval, and chemotherapy.TM Information was
collected on prevalence changes, but a cost-ef
fectiveness ratio was not calculated and since no
alternative control measures were evaluated, it
is not possible to tell whether any different mix
of strategies would be less costly or more effec
tive. However, the study does give an idea on
the vital issue of affordability and whether such
control measures could be sustained.
Rajagopolan and Panicker presented another
partialanalysisthatfocusedon describingthe
consequences of vector control.35 They quanti
fied the direct socioeconomic benefits of mos
quito control activities in a coastal village in
Pondicherry, India. Activities included econom
ic exploitation of algae and prawn culture, both
of which contributed to mosquito control and
also generated income. Although the income
from the schemes is stated, it is not clear wheth
er this is pure profit or whether production costs
should be deducted. However, the study high
lights an important category of benefit that is
particularly relevant to environmental manage
ment strategies.
Schofield and Dias assessed the value of pre
venting Chagas' disease by comparing control
costs (of house spraying) only with saved med
ical care costs and avoidance of the cost of fu
nerals for deaths occurring in the acute phase.@
They term the study a cost-benefit analysis, al
though it is a partial one since it does not quan
tify other benefits. Their justification is that con
trol is evidently worthwhile even on the basis of
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their limited consideration of benefits. However,
their treatment costs saved are hypothetical, as
they admit, in that they assume that everyone
who requires care would get it. Moreover, they
assume that their estimated costs of medical care
reflect the value, in their alternative use, of the
resources saved when, for example, fewer pace
makers or less corrective digestive surgery are
required. The existing average costs of treatment
do not necessarily represent the resources saved
(e.g., some resources may be used also by other
services and may not be released); also, not all
the resources released may be productively used.
The general approach of this study, to com
pare costs of prevention with saved treatment
costs, can indicate worthwhile interventions.
However, two caveats are necessary: first, even
if an intervention is not justified by reference to
saved treatment costs, it does not necessarily fol
low that it is not worth implementing, since
health improvement is valued for its own sake.
Second, the poorer the country (or geographic
area within the country), the less extensive will
be the health infrastructure and thus the smaller
the potentialsavings.Thus, an analyticalap
proach that focuses on efficiency improvements
can contradict distributional objectives to im
prove the position of the worst-off that would
givehighprioritytopooreror poorestareas.
The comparison of strategieswithinvector
controlis ideallysuitedto cost-analysisand
cost-effectivenessanalysisbecause the various
strategies tend to have a number of endpoints in
common, and useful conclusions can be derived
without necessarily having information on
health effects. Phillips and Mills, for example,
compared the costs of spraying three insecti
cides, DDT, Malathion and Ficam (bendiocab),
concentrating particularly on the costs of deliv
ering the insecticides to house walls, since these
are costs often ignored by researchers but are
frequently paid locally (rather than by donors).37
Although DDT was by far the cheapest per
house sprayed, and also had the lowest nonin
secticide costs, the choice of chemical in Nepal
depended primarily on donor preference, a com
mon constraint in achieving economic efficien
cy. Gandahusada and others analyzed costs for
fenitrothion spraying only, but compared two
cycles of full coverage and one of selective cov
erage with three cycles of selective coverage.38
Data on epidemiologic endpoints were collected
and cost-effectiveness ratios could have been
calculated, although the study computed only
cost per person protected. Both strategies re
duced malaria rates and vector populations to
very low levels (although full coverage achieved
this reduction more quickly), but selective treat
ment was 68% cheaper than full coverage. As
more expensive insecticides are used, the insec
ticide share of the total cost tends to be greater,
as does the potential savings from more selec
tive coverage.39
When the strategy of vector control is being
compared with alternative strategies of preven
tion or treatment for the same disease, cost anal
ysis tends to be less useful than cost-effective
ness analysis because the strategies compared
may have different effects. Jordan reported the
results of a comparative evaluation of snail con
trol, chemotherapy and provision of water sup
plies for schistosomiasis control in St Lucia.4Â°
Annual costs per capita, rather than cost-effec
tiveness ratios, were calculated, and were lowest
for chemotherapy, followed by snail control and
water supplies. Epidemiologic data showed that
chemotherapy was the procedure most rapidly
effective, and also provided treatment benefits.
A subsequent calculation of cost per case year
averted confirmed the ranking of the interven
tions,32 so in this instance, cost analysis alone
was not misleading. However, this study indi
cates one of the classic problems of cost-effec
tiveness analysis: finding an indicator of effec
tiveness that adequately reflects all the
consequences of the alternatives. In this study,
cases prevented is clearly only a partial measure
of the consequences of water supplies; they are
evaluated only in terms of their contribution to
schistosomiasis control, and other social benefits
are ignored.
A classic cost-effectiveness study of alterna
tive strategies for schistosomiasis control used
decrease in prevalence at the end of seven years
of control and case years of infection prevented
as indicators of effectiveness.4' The main inter
est of this study is that a transmission model was
used to model the impact of control alternatives.
This not only makes it relatively easy to explore
the implications of alternative values for the
variables in the model (termed sensitivity anal
ysis), but also facilitates handling the compari
son of alternative mixes and timing of strategies.
A modeling approach was also adopted in a
comparison of vector control and case finding
and treatment for human trypanosomiasis.4 The
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study is of particular interest because it tackles
a problem common to comparisons of vector
control and treatment: how to define the unit of
effectwhen one strategypreventsdiseaseand
the other treats. The study describes itself as an
alyzing costs and benefits, but since the benefit
unit is defined as the prevention of one year of
infection (so the stream of benefits over time is
the difference between prevalence with control
and without control), it is more appropriately de
scribed as a cost-effectiveness study. In this
case, the model is a very simple one, confined
to analyzing the relationships between costs and
effects. However, the paper is unusual in dis
cussing cost determinants, and demonstrates
how a spreadsheet model can help to identify the
most important variables.
The comparisonof interventionsagainstvery
different diseases is of less relevance to a vector
controlprogram manager,but of importanceto
national decision-makers who need to set pri
orities. Prost and Prescott, having estimated the
cost-effectiveness of blindness prevention by the
Onchocerciasis Control Programme in terms of
healthy years of life gained, made an illustrative
comparison with the cost-effectiveness of mea
sles immunization.42 They found that the relative
attractiveness of blindness prevention depended
on the effectiveness measure: the measure of
discounted productive years of healthy life
gained favored blindness prevention, whereas
undiscounted measures and including all years
of life favored measles immunization. This em
phasizes the importance of careful choice of ef
fectiveness measure and of explicit discussion of
the values inherent in the measure used. A much
more extensive comparison of disease control
priorities has been undertaken by Jamison and
others.9 They rank measures to improve child
health and adult health (including vector control)
in terms of the cost per disability adjusted life
year gained. As they state, such a ranking can
only illustrate the potential cost-effectiveness of
alternative interventions: actual cost-effective
ness can vary enormously between countries de
pending on a variety of local circumstances.
Thus, the relevance of their conclusions must be
checked at the country level by those countries
wishingto applythe same approachto priority
setting.
Although all of the above studies help to shed
some light on the choices in vector control and
on methods of analysis, this brief review high
lights some important methodologic concerns.
First, many studies do not bother to compare
alternatives, although little can be concluded on
the basis of a single-cost per capita or cost-per
health effect. Second, studies done by econo
mists tend to lack good epidemiologic data, and
studies done by epidemiologists and scientists
often lack good cost data; indeed, cost-effective
ness ratios may not be calculated even when the
data are available to do so. Third, excessive at
tention is given to quoting cost per capita mea
sures. These can be quite misleading, since the
denominator will include people receiving no
benefit (those with natural immunity, those liv
ing in pockets of zero transmission, those who
fall ill despite the control activities, those who
were infected prior to the control project).32 Fi
nally, it is evident that the levels of transmission
of vector-borne diseases can vary considerably
from one area to another, even within a country,
totheextentthatthechoiceofcontrolstrategies
may be different in different locations. Thus, an
alysts should include in their studies considera
tion of the factors that may influence cost-effec
tiveness so that the applicability of the
conclusions elsewhere can be considered.
The fact that useful policy implications can
be drawn, as indicated in the above review, from
imperfect studies is not an excuse for poor an
alytic approaches. However, methodologic pu
rity and perfect data should not be sought for
their own sake. For some policy and planning
issues, crude data may be sufficient to provide a
clear answer; for others, a carefully designed
study may have to be set up. It is incumbent on
the analyst to judge the level of effort necessary
toprovidean answer;indeed,toapplytheprin
ciples of cost-effectiveness analysis to his or her
own activities!
THE OUTLOOK FOR THE FUTURE
Several reviews of economic evaluation lit
erature relevant to vector control strategies for
controllingtropicaldiseaseshave concludedthat
we do not yet know enough to provide clear ad
vice on choice of control strategy. For example,
Barlow and Grobar identified three main conclu
sions from their very extensive review of para
sitic disease control:32 1) there are substantial
gaps in knowledge about cost-effectiveness and
cost-benefit ratios, 2) there appear to be big dif
ferences in the cost-effectiveness of alternative
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means of control, and 3) the cost-effectiveness
of a given control strategy can vary widely from
location to location.
To these, Kaewsonthi adds the concern that
knowledge of costs and effectiveness do not by
themselves produce changes in organizations,
especially where there are long established prac
tices.43
It is clear that spraying is costly and often
ineffective,â€• and that community participation
and environmental management have the poten
tial to control certain vectors in certain circum
stances at low cost.â€•â€•However, more studies are
needed before useful conclusions can be drawn
that will help program managers decide which
vector control strategies or mix of strategies are
most cost-effective.
The outlook for the future would be much im
proved if the following methodologic guidance
was followed: 1) whenever possible and rele
vant,researchon controlstrategiesshouldhave
both epidemiologic and economic components,
2) more attention should be paid to producing
good quality cost data and also to considering
the determinants of cost and effectiveness in a
particular site so that the relevance of the find
ings to other locations can be considered, and 3)
computer models can be used successfully to
manipulatethevariablesintheanalysisand un
dertake sensitivity analysis.
In terms of research priorities, cost-effective
ness analysis of routine control activities, which
involves the control staff so that they are en
couraged to implement changes, is obviously
important to improve efficiency. So is including
an economic component in the evaluation of
new control technologies to check that they are
not only effective but also cost-effective. There
appears to be a strong demand from policy mak
ers for information on the impact of disease on
production. There is some scope for more so
phisticated econometric modeling, but it is also
important to use qualitative techniques to ex
plore in depth how households cope with illness
and disability;45 these will help to develop hy
potheses that can later be tested using more
quantitative approaches.
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